Conference PaperPDF Available

A Partial Budget Analysis to Estimate the Economics of a Mastitis Vaccination Program

Authors:
  • DairyExperts, Tulare, CA

Abstract

STARTVACR is a vaccine aimed to reduce mastitis caused by Staphylococcus aureus, Escherichia coli and coagulase-negative staphylococci. The objective of this economical analysis was to estimate the net profit of vaccination using data from a clinical trial where 343 cows from six Spanishherds were randomized either to a control (C) or a vaccination group (V). Outcomes were evaluated up to 130 days after parturition. The economic value of the reduction in the days that milk was discarded was estimated by multiplying the difference between both study groups (C = 1.6 days; V = 0.9 days; Diff. = 0.7 days) by daily milk production (30 kg/cow) and milk price (0.30 €/kg). A cost of € 46 per casewas used in the calculation of the reduction in treatment costs due to less clinical mastitis (C = 15%; C = 4%; Diff. = 11%). Although there was a reduction in SCC weighted by the cow’s milk production (C = 559,000 cells/ml; V = 431,000 cells/ml), no additional revenues were estimated because SCC did not drop below the 250,000 cutoff point used by most milk processors in Spain to pay premiums. In the estimation of the reduction in culling costs (C = 9%; V = 5%; Diff. = 4%), the cost of a cull cow was estimated as the average value of a cow in the herd minus the average cull cow’s salvage value (€ 1,250 - € 500 = € 750). The vaccination program costs were estimated in € 17 per cow and lactation. The overall net profit of the vaccination intervention was €25 per cow in the first 130 after parturition (direct effects). In addition, the observed reduction in subclinical mastitis incidence (C = 46%; V = 18%) is expected to result on a reduction of cow-to-cow transmission of mastitis pathogens (indirect effects).
RESULTS
INTRODUCTION
Mastitis remains the most costly infectious disease, and the most
frequent cause of antibacterial use on commercial dairy farms.
The use of vaccination to control infectious diseases in dairy cattle is
common and vaccination against mastitis pathogens is a control
strategy used by some dairy farmers.
STARTVAC® is an inactivated vaccine aimed to reduce bovine
mastitis problems caused by Staphylococcus aureus, Escherichia coli
and coagulase-negative staphylococci.Table 1: Input variables obtained from a clinical trial evaluating the
STARVAC® vaccine in six dairies.
Figure 3: Histogram representing the impact of input variables on the
intervention net profit per cow.
A Partial Budget Analysis to Estimate the Economics of a Mastitis Vaccination Program
Lago1, A.; Guix2, R.; March2, R.; Noguera2, M.; Foix2, A.; Prenafeta2, T.
1DairySER, California, USA
2Hipra, Girona, Spain
MATERIALS AND METHODS
Data from a multiherd, randomized, double-blinded, controlled and
stratified (primiparous and multiparous) trial evaluating the efficacy of a
STARTVAC® vaccination program was used in this economic analysis.
Three hundred and forty three cows from six Spanish herds were
randomly assigned at 45 days prior to the estimated parturition date to
either a control group (Control) or to a vaccination group (STARTVAC).
Cows assigned to the STARVAC group were vaccinated with
STARTVAC® at 45 and 10 days prior to the estimated parturition date
and 52 days after parturition.
Input variables (up to 130 days after parturition) that were used in the
economic analysis included: a) days of discarded milk obtained from
study records; b) milk yield obtained from weekly measurements; c)
somatic cell count (SCC) obtained from weekly measurements; d) new
intramammary infection risk obtained from weekly cultures from
composite samples; e) clinical mastitis incidence; and, f) cow survival
(culling and death events) obtained from study records.
The economic value of input variables was based on literature, if
available, or on the Spanish market.
SUMMARY
The overall net profit of the vaccination intervention was €25 per cow
in the first 130 after parturition (direct effects).
The input variable that had the strongest impact on the profitability of
the vaccination program was the reduction in culling experimented by
vaccinated cows.
The vaccine was very efficacious in reducing the incidence of clinical
mastitis during lactation which indicates that the profitability of the
vaccination program is expected to be directly correlated with the herd
incidence of clinical mastitis.
In addition, the observed reduction in subclinical mastitis incidence is
expected to result on a reduction of cow-to-cow transmission of
mastitis pathogens (indirect effects). This effects were not estimated
in this partial budget.
Breakeven was less than half (40%) of the expected effect size even
when only considering the direct effects of the vaccine.
Figure 4: Net profit and return on investment (ROI) per cow when
accounting for direct effects alone using effect sizes of 200% and 50%.
Figure 1: Economic value assigned to input variables.
Direct Effects
17$ vaccination cost
16.00 vaccine cost
3 min / cow
8.00 labor (€/hour)
0.30 syringes costs
0.08 marginal feed cost per kg of milk
0.30 milk price per kg
250,000 cut-point SCC premium
0.01 premium per kg of milk at <250,000 cells/ml
46$ treatment costs per clinical mastitis case
30.00 drugs
10.00 labor
30.00 vet cost per call
20% cases seen by the vet
750.00 cost of an averge cull
1,250.00 value of existing average cow
2,000.00 price of a new heifer
500.00 income from beef
Indirect Effects
77.00 reduced costs because of reduced transmission
1.00
77.00 cost of a subclinical mastitis case
OBJECTIVES
Determine revenues and costs resulting from implementing a
STARTVAC® vaccination program.
Develop a deterministic simulation model using partial budgeting to
estimate the net profit of implementing a STARTVAC® vaccination
program.
€20 10 €0 €10 20 €30 40
vaccination cost
clinical mastitis treatment
days of discarded milk
culling
Intervention Outcomes Economic
Value
Control (0-130 DIM)
discarded milk (days) 1.6
average daily milk yield (kg) 32
average SCC (cells/ml) 559,000
clinical mastitis risk 15%
subclinical mastitis risk 46%
culling risk 9%
STARTVAC® (0-130 DIM)
discarded milk (days) 0.9
average daily milk yield (kg) 30
average SCC (cells/ml) 431,000
clinical mastitis risk 4%
subclinical mastitis risk 18%
culling risk 5%
Extra / reduced revenues
milk production NSD
SCC premiums -
Reduced / extra costs days of discarded milk 7
clinical mastitis treatment 5
culling 30
marginal feed cost NSD
vaccination cost (17)
STARTVA net profit per cow 25
Control (0-130 DIM)
discarded milk (days) 1.6
average daily milk yield (kg) 32
average SCC (cells/ml) 559,000
clinical mastitis risk 15%
subclinical mastitis risk 46%
culling risk 9%
STARTVA (0-130 DIM)
discarded milk (days) 0.9
average daily milk yield (kg) 30
average SCC (cells/ml) 431,000
clinical mastitis risk 4%
subclinical mastitis risk 18%
culling risk 5%
Figure 3: Extra or reduced revenues and costs per cow resulting from
using a STARVAC® vaccination program in six dairies, as well as
direct net profits from the intervention.
Cows
People
D
D
Da
a
ai
i
ir
r
ry
y
yS
S
SE
E
ER
R
R
Effect size 200% 50%
STARTVAC® net profit per cow € 67 € 4
Return on investment (ROI) 399% 25%
Breakeven (Effect size) 40%
Full-text available
Article
Bu çalışmada, Çanakkale ili Biga ilçesinde süt sığırcılığı faaliyetinde bulunan işletmecilerin hayvanlarını mastitis hastalığından korumak için düzenli olarak mastitis aşısı yaptırmalarının işletme gelirleri üzerine olan etkilerinin belirlenmesi amaçlanmıştır. Çalışmanın ana materyalini, Biga ilçesi ve köylerinden tabakalı tesadüfi örnekleme yöntemiyle belirlenen 179 işletme içerisinden bazı kriterler dikkate alınarak seçilen 10 işletmeden Aralık 2012-Şubat 2013 dönemleri arasında anket yoluyla elde edilen veriler oluşturmaktadır. Mastitis aşı uygulamasının işletmeler için brüt ekonomik faydasının hesaplanmasında, kısmi bütçe modeli kullanılmıştır. Bu modelin sonuçlarına göre; mastitis aşı uygulamasının işletmeler için brüt ekonomik faydası 225.8 TL/baş olarak bulunmuştur.
ResearchGate has not been able to resolve any references for this publication.